Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Accumulated Depreciation (2016)

Agios Pharmaceuticals (AGIO) has disclosed Accumulated Depreciation for 3 consecutive years, with $13.4 million as the latest value for Q4 2016.

  • For the quarter ending Q4 2016, Accumulated Depreciation rose 74.48% year-over-year to $13.4 million, compared with a TTM value of $13.4 million through Dec 2016, up 74.48%, and an annual FY2016 reading of $13.4 million, up 74.48% over the prior year.
  • Accumulated Depreciation was $13.4 million for Q4 2016 at Agios Pharmaceuticals, up from $7.7 million in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $13.4 million in Q4 2016 and bottomed at $2.8 million in Q4 2012.
  • Average Accumulated Depreciation over 3 years is $7.9 million, with a median of $7.7 million recorded in 2015.
  • Peak annual rise in Accumulated Depreciation hit 74.48% in 2016, while the deepest fall reached 74.48% in 2016.
  • Year by year, Accumulated Depreciation stood at $2.8 million in 2012, then soared by 178.59% to $7.7 million in 2015, then soared by 74.48% to $13.4 million in 2016.
  • Business Quant data shows Accumulated Depreciation for AGIO at $13.4 million in Q4 2016, $7.7 million in Q4 2015, and $2.8 million in Q4 2012.